Outlook Therapeutics

Oncobiologics is a privately held biopharmaceutical company focused on the development and commercialization of biosimilar monoclonal antibodies. It is advancing a pipeline of 11 biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates a state-of-the-art, fully integrated 50,000-square-foot R&D and manufacturing facility in Cranbury, New Jersey. The company utilizes its BioSymphony™ biosimilar business model to achieve accelerated development and technical excellence, creating affordable medicines for patients worldwide.On December 3, 2018, Oncobiologics Inc. announced its official name change to Outlook Therapeutics, Inc.